Related Experiment Video
Updated: May 21, 2025
10:21
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
9.9K
Pbx3-mediated suppression of type I interferon response contributes to leukemia progression driven by MLL-AF9
Li Tang1, Meng Lu1, Yulong Du1
1School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China.
Cancer Gene Therapy
|March 20, 2025
Summary
Acute myeloid leukemia (AML) progression involves decreased interferon response, driven by Pbx3. Type I interferon therapy shows potential for treating MLL-AF9 AML by inducing differentiation and delaying disease.
Area of Science:
- Hematology
- Cancer Biology
- Immunology
Background:
- Cell-intrinsic inflammation supports acute myeloid leukemia (AML) survival.
- The dynamics of cell-intrinsic inflammation during AML progression are not well understood.
Purpose of the Study:
- To investigate the role of cell-intrinsic inflammation in MLL-AF9-driven AML progression.
- To explore the therapeutic potential of type I interferon in AML.
Main Methods:
- CRISPR-mediated genome editing to establish a murine AML model.
- Analysis of gene expression changes during leukemia progression.
- Interferon-α (IFNα) administration and inhibition of MLL-AF9 transcriptional activity.
Main Results:
- Leukemia progression correlated with downregulated type I interferon response genes.
- Pbx3 upregulation in progenitor cells was critical for suppressing interferon response.
- IFNα administration induced leukemic cell differentiation.
- Combined IFNα therapy and inhibition of MLL-AF9 transcriptional activity delayed leukemia progression.
Conclusions:
- Pbx3-mediated suppression of interferon response genes is crucial for MLL-AF9 AML progression.
- Type I interferon represents a promising therapeutic strategy for MLL-AF9 AML.
